Pular para o conteúdo principal
Ranking Invest

ATAI - Atai Life Sciences N.V.

Segmento: HealthcareAtai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Análise Ranking Invest

Valor de Mercado
$ 2.73 Bi
IVR
-0.10Índice proprietário de comparação relativa: -0,10.
IVR2
-0.17Leitura proprietária complementar: -17%.
MLL
-0.17Leitura proprietária complementar: -17%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 176.29 Mi

Dívida Líquida

-$ 145.81 Mi

L4T

-$ 127.69 Mi

MM4T

193107.44%

Indicadores Básicos

ROE

-72.43%

Índices de Previsibilidade

Receita Líquida

G4.35

Lucro

C0.29

Margem

E1.11

Índices de Tendência

Receita Líquida

C7.52

Lucro

B5.08

Margem

C3.85

Índices de Endividamento

DIV/PAT

-0.83

DIV/L4T

1.14

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.